- GPhA: FDA’s proposed rule on prescription drug labeling adds $4 billion to healthcare costs
- 21 health industry groups address FDA on proposed changes to generic drug label rules
- Roxane Labs' generic prostate drug gets tentative approval from FDA
- NACDS, NCPA, GPhA express support for Drug Quality and Security Act
- Senate passes Drug Quality and Security Act
PARSIPPANY, N.J. — The Medicines Co. and generic drug maker Teva Pharmaceutical Industries have reached a settlement that will allow Teva to start selling a generic version of one of MDCO's drugs by the end of the decade.
The drug makers announced the settlement in the U.S. District Court for the District of Delaware, whereby Teva can launch a generic version of the injectable anticoagulant drug Angiomax (bivalirudin) in June 2019.
Under the settlement, Teva admits that two patents covering Angiomax are valid, enforceable and would be infringed by Teva's generic version. The patents are scheduled to expire in July 2028, according to the Food and Drug Administration. MDCO remains in infringement litigation concerning the drug with generic drug makers APP Pharmaceuticals, Hospira, Mylan and Dr. Reddy's Labs.